Grafa News and Videos — Page 612

ANZ Bank New Zealand has announced that its CEO and ANZ Group (ASX:ANZ) executive, Antonia Watson, will retire.

Beetaloo Energy (ASX:BTL) flagged a mid-June commencement for its critical Carpentaria-5H extended production test.

Australia's economic engine is stalling as labour productivity slipped by 0.6% in the March quarter.

Genmab (NASDAQ:GMAB) announced new data from a post-hoc subgroup analysis of its pivotal Phase 3 EPCORE FL-1 trial, which evaluates the subcutaneous T-cell engaging bispecific antibody epcoritamab in combination with rituximab and lenalidomide (epcoritamab plus R2).

Canaan (NASDAQ:CAN) announced its unaudited operational updates for May 2026, highlighting significant advancements in energy efficiency and geographic infrastructure expansions.

C4 Therapeutics (NASDAQ:CCCC) reported updated clinical data from its Phase 1 trial evaluating cemsidomide, an investigational oral molecular glue degrader targeting IKZF1/3, for the treatment of relapsed or refractory multiple myeloma.

Purple Biotech (NASDAQ:PPBT) unveiled new preclinical data for IM1240, its lead T-cell engager candidate utilizing the proprietary CAPTN-3 platform, at the European Association for Cancer Research (EACR) 2026 Congress.

Climb Bio (NASDAQ:CLYM) reported positive initial Phase 1b clinical data for its drug candidate budoprutug, an anti-CD19 monoclonal antibody, which is being developed to treat adults with primary immune thrombocytopenia.

Vera Bradley (NASDAQ:VRA) reported an unexpected rise in profit margins and its first quarterly top-line expansion in over four years, signaling that its comprehensive brand overhaul is beginning to resonate with retail consumers.

Syndax Pharmaceuticals (NASDAQ:SNDX) unveiled a broad array of clinical data reinforcing the therapeutic profile of its approved blood cancer drug, Revuforj, across several distinct mutations and stages of acute leukemia.